載入...
Phase II Study of the Src Kinase Inhibitor Saracatinib (AZD0530) in Metastatic Melanoma
BACKGROUND: Src kinases are activated in melanoma, and inhibition of Src kinase activity has preclinical anti-tumor effects. Targeting this pathway could therefore have therapeutic activity in patients with metastatic melanoma. PATIENTS AND METHODS: We conducted a multi-center, open-label study of t...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2012
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3600382/ https://ncbi.nlm.nih.gov/pubmed/23151808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9897-4 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|